Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
BioLineRx Ltd. logo

NASDAQ · BLRX

BioLineRx Ltd.

Healthcare · Biotechnology

$1.86

Down-$0.05 (-2.62%)

Updated Nov 5, 2026, 5:01 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.09M
P/E ratio
-1.61
Dividend yield
0.00%
52-week range
$1.90 – $3.95
Volume
8.88K
Avg. volume
34.05K

Price performance · BLRX

BLRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

BLRX closed at $1.86 after 21 trading sessions, down 15.65% for the selected period.

Last close
$1.86
Period change
-15.65%
Period low
$1.86
Period high
$2.22
Daily close
View OHLC price history
BLRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$1.81$1.92$1.81$1.868.88K
Nov 3, 2026$1.94$1.99$1.90$1.9113.37K
Nov 2, 2026$1.94$1.96$1.94$1.964.71K
Oct 30, 2026$1.95$1.9913$1.94$1.998.79K
Oct 29, 2026$2.01$2.02$1.94$2.024.15K
Oct 28, 2026$1.94$2.04$1.94$2.004.04K
Oct 27, 2026$1.97$2.03$1.96$2.034.99K
Oct 26, 2026$2.15$2.15$1.98$2.018.04K
Oct 23, 2026$2.04$2.11$2.04$2.041.7K
Oct 22, 2026$2.07$2.166$1.99$2.06355.2K
Oct 21, 2026$2.19$2.19$1.96$2.111.86K
Oct 20, 2026$2.07$2.2145$2.07$2.21453.06K
Oct 19, 2026$2.07$2.1599$1.96$1.9834.66K
Oct 16, 2026$2.30$2.30$1.985$2.0112.58K
Oct 15, 2026$2.03$2.165$1.945$2.0528.75K
Oct 14, 2026$2.18$2.18$2.0101$2.07523.53K
Oct 13, 2026$2.27$2.27$2.11$2.1711.75K
Oct 12, 2026$2.22$2.3443$2.14$2.1728.17K
Oct 9, 2026$2.20$2.2703$2.20$2.2169.69K
Oct 8, 2026$2.31$2.31$2.17$2.2118.37K
Oct 7, 2026$2.28$2.3698$2.16$2.20524.04K

Latest BLRX news

The latest Smart Investors Daily articles mentioning BLRX.

Stock researchCompany · Overview

BLRX research

Overview

Company profile and research snapshot.

Company profile

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BLRX recent ratings
DateFirmRatingTarget
Dec 16, 2020HC Wainwright & Co.Buy—
Aug 4, 2017OppenheimerOutperform—
May 18, 2017Maxim GroupBuy—
Feb 13, 2017Rodman & RenshawBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) , a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced today that the companies presented data at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026) demonstrating synergy between GLIX1 and multiple PARP inhibitors (PARPi) in homologous recombination (HR)-proficient ov

Yahoo · Oct 8, 2026

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By